{
  "source": "PA-Med-Nec-SLIT.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 2029-15\nProgram Prior Authorization/Medical Necessity - Sublingual Immunotherapy (SLIT)\nMedication Sublingual Immunotherapy (SLIT) - Grastek (Timothy grass pollen allergen\nextract), Odactra (Dermatophagoides farinae/Dermatophagoides\npteronyssinus allergen extract), Oralair (Sweet Vernal, Orchard, Perennial\nRye, Timothy, and Kentucky Blue Grass Mixed Pollens allergen extract),\nRagwitek (Short Ragweed Pollen allergen extract)\nP&T Approval Date 5/2014, 5/2015, 4/2016, 4/2017, 3/2018, 3/2019, 3/2020, 3/2021, 9/2021,\n3/2022, 3/2023, 3/2024, 3/2025\nEffective Date 6/1/2025\n1. Background:\nThe sublingual immunotherapy (SLIT) medications are indicated for patients who have\nsymptoms of allergic rhinitis with natural exposure to allergens and who demonstrate specific\nIgE antibodies to the relevant allergen. Grastek (Timothy grass pollen allergen extract) and\nOralair (Sweet Vernal, Orchard, Perennial Rye, Timothy, and Kentucky Blue Grass Mixed\nPollens allergen extract) are indicated for patients with grass pollen-induced allergic rhinitis,\nRagwitek (short ragweed pollen allergen extract) is indicated for ragweed pollen-induced\nallergic rhinitis and Odactra (Dermatophagoides farinae/Dermatophagoides pteronyssinus\nallergen extract), is indicated for house dust mite (HDM)-induced allergic rhinitis.\nCandidates for allergen immunotherapy are patients whose symptoms are not adequately\ncontrolled by medications, and avoidance measures have been ineffective. In addition, patients\nexperiencing unacceptable adverse effects of medications or who wish to reduce the long-term\nuse of medications may also be candidates for immunotherapy.\n2. Coverage Criteriaa:\nA. Grastek\n1. Initial Authorization\na. Grastek will be approved based on all of the following:\n(1) Diagnosis of moderate to severe grass pollen-induced allergic rhinitis defined by\nsymptoms severe enough to interfere with quality of life (e.g., sleep disturbances;",
    "based on all of the following:\n(1) Diagnosis of moderate to severe grass pollen-induced allergic rhinitis defined by\nsymptoms severe enough to interfere with quality of life (e.g., sleep disturbances;\nimpairment of daily, sport, or leisure activities; impairment of school or work\nperformance)\n-AND-\n(2) Diagnosis confirmed by one of the following:\n© 2025 UnitedHealthcare Services Inc.\n1\na. Positive skin test to Timothy grass or cross-reactive grass pollens (e.g., Sweet\nVernal, Orchard/Cocksfoot, Perennial Rye, Kentucky blue/June grass, Meadow\nFescue, or Redtop)\nb. in vitro testing for pollen-specific IgE antibodies for Timothy grass or cross-\nreactive grass pollens (e.g., Sweet Vernal, Orchard/Cocksfoot, Perennial Rye,\nKentucky blue/June grass, Meadow Fescue, or Redtop)\n-AND-\n(3) Treatment is started or will be started at least 12 weeks before the beginning of the\ngrass pollen season\n-AND-\n(4) History of failure, contraindication, or intolerance to two of the following:\na. oral antihistamine [e.g. cetirizine (Zyrtec)]\nb. intranasal antihistamine [e.g. azelastine (Astelin)]\nc. intranasal corticosteroid [e.g. fluticasone (Flonase)]\nd. leukotriene inhibitor [e.g. montelukast (Singulair)]\n-AND-\n(5) Not received in combination with similar cross-reactive grass pollen immunotherapy\n(e.g., Oralair)\n-AND-\n(6) Patient does not have unstable and/or uncontrolled asthma\n-AND-\n(7) Prescribed by or in consultation with a specialist in allergy and immunology\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Grastek will be approved based on the following criterion:\n(1) Documentation of positive clinical response to Grastek therapy\nAuthorization will be issued for 12 months.\nB. Oralair\n1. Initial Authorization\na. Oralair will be approved based on all of the following:\n© 2025 UnitedHealthcare Services Inc.\n2\n(1) Diagnosis of moderate to severe grass pollen-induced allergic rhinitis defined by\nsymptoms severe enough to interfere with quality of life (e.g., sleep distur",
    "2025 UnitedHealthcare Services Inc.\n2\n(1) Diagnosis of moderate to severe grass pollen-induced allergic rhinitis defined by\nsymptoms severe enough to interfere with quality of life (e.g., sleep disturbances;\nimpairment of daily, sport, or leisure activities; impairment of school or work\nperformance)\n-AND-\n(2) Diagnosis confirmed by one of the following:\na. Positive skin test to any of the five grass species contained in Oralair [(i.e., Sweet\nVernal, Orchard, Perennial Rye, Timothy, and Kentucky Blue grass mixed\npollens) or cross-reactive grass pollens (e.g., Cocksfoot, Meadow Fescue, or\nRedtop)]\nb. in vitro testing for pollen-specific IgE antibodies for any of the five grass species\ncontained in Oralair [(i.e., Sweet Vernal, Orchard, Perennial Rye, Timothy, and\nKentucky Blue grass mixed pollens) or cross-reactive grass pollens (e.g.,\nCocksfoot, Meadow Fescue, or Redtop)]\n-AND-\n(3) Treatment is started or will be started at least 4 months before the beginning of the\ngrass pollen season\n-AND-\n(4) History of failure, contraindication, or intolerance to two of the following:\na. oral antihistamine [e.g. cetirizine (Zyrtec)]\nb. intranasal antihistamine [e.g. azelastine (Astelin)]\nc. intranasal corticosteroid [e.g. fluticasone (Flonase)]\nd. leukotriene inhibitor [e.g. montelukast (Singulair)]\n-AND-\n(5) Not received in combination with similar cross-reactive grass pollen immunotherapy\n(e.g., Grastek)\n-AND-\n(6) Patient does not have unstable and/or uncontrolled asthma\n-AND-\n(7) Prescribed by or in consultation with a specialist in allergy and immunology\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Oralair will be approved based on the following criterion:\n© 2025 UnitedHealthcare Services Inc.\n3\n(1) Documentation of positive clinical response to Oralair therapy\nAuthorization will be issued for 12 months.\nC. Ragwitek\n1. Initial Authorization\na. Ragwitek will be approved based on all of the following:\n(1) Diagnosis of moderate to severe short ragweed pollen",
    "py\nAuthorization will be issued for 12 months.\nC. Ragwitek\n1. Initial Authorization\na. Ragwitek will be approved based on all of the following:\n(1) Diagnosis of moderate to severe short ragweed pollen-induced allergic rhinitis\ndefined by symptoms severe enough to interfere with quality of life (e.g., sleep\ndisturbances; impairment of daily, sport, or leisure activities; impairment of school or\nwork performance)\n-AND-\n(2) Diagnosis confirmed by one of the following:\na. Positive skin test to short ragweed pollen\nb. in vitro testing for pollen-specific IgE antibodies for short ragweed pollen\n-AND-\n(3) Treatment is started or will be started at least 12 weeks before the beginning of the\nshort ragweed pollen season\n-AND-\n(4) History of failure, contraindication, or intolerance to two of the following:\na. oral antihistamine [e.g. cetirizine (Zyrtec)]\nb. intranasal antihistamine [e.g. azelastine (Astelin)]\nc. intranasal corticosteroid [e.g. fluticasone (Flonase)]\nd. leukotriene inhibitor [e.g. montelukast (Singulair)]\n-AND-\n(5) Patient does not have unstable and/or uncontrolled asthma\n-AND-\n(6) Prescribed by or in consultation with a specialist in allergy and immunology\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Ragwitek will be approved based on the following criterion:\n© 2025 UnitedHealthcare Services Inc.\n4\n(1) Documentation of positive clinical response to Ragwitek therapy\nAuthorization will be issued for 12 months.\nD. Odactra\n1. Initial Authorization\na. Odactra will be approved based on all of the following:\n(1) Diagnosis of house dust mite (HDM)-induced allergic rhinitis\n-AND-\n(2) Diagnosis confirmed by one of the following:\n(a) Positive skin test to licensed house dust mite allergen extracts\n(b) in vitro testing for IgE antibodies to Dermatophagoides farinae or\nDermatophagoides pteronyssinus house dust mites\n-AND-\n(3) History of failure, contraindication, or intolerance to two of the following:\na. oral antihistamine [e.g. cetirizine (Zyrtec)]\n",
    "des farinae or\nDermatophagoides pteronyssinus house dust mites\n-AND-\n(3) History of failure, contraindication, or intolerance to two of the following:\na. oral antihistamine [e.g. cetirizine (Zyrtec)]\nb. intranasal antihistamine [e.g. azelastine (Astelin)]\nc. intranasal corticosteroid [e.g. fluticasone (Flonase)]\nd. leukotriene inhibitor [e.g. montelukast (Singulair)]\n-AND-\n(4) Patient does not have unstable and/or uncontrolled asthma\n-AND-\n(5) Prescribed by or in consultation with a specialist in allergy and immunology\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Odactra will be approved based on the following criterion:\n(1) Documentation of positive clinical response to Odactra therapy\nAuthorization will be issued for 12 months.\n© 2025 UnitedHealthcare Services Inc.\n5\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class\n• Supply limits and/or Notification may be in place.\n4. References:\n1. Grastek® [package insert]. Blagrove Swindon Wiltshire, UK: Catalent Pharma Solutions\nLimited; September 2022.\n2. Oralair® [package insert]. Lenoir, NC: Greer Laboratories, Inc.: September 2022.\n3. Ragwitek® [package insert]. Blagrove Swindon, Wiltshire, UK: Catalent Pharma Solutions\nLimited; September 2022.\n4. Odactra® [package insert]. Blagrove Swindon, Wiltshire, UK: Catalent Pharma Solutions\nLimited: May 2023.\n5. Cox, L, Nelson, H, Lockey, R, et al. Allergen immunotherapy: A practice parameter third\nupdate. American Academy of Allergy, Asthma & Immunology. December 2010.\n6. Treatment of seasonal",
    ": May 2023.\n5. Cox, L, Nelson, H, Lockey, R, et al. Allergen immunotherapy: A practice parameter third\nupdate. American Academy of Allergy, Asthma & Immunology. December 2010.\n6. Treatment of seasonal allergic rhinitis: An evidence-based focused 2017 guideline update.\nDykewicz MS, Wallace DV, Baroody F, et.al. Ann Allergy Asthma Immunol. 2017\nDec;119(6):489-511.e41\n7. Sublingual immunotherapy: A focused allergen immunotherapy practice parameter update.\nGreenhawt M, Oppenheimer J, Nelson M, et.al. Ann Allergy Asthma Immunol. 2017\nMar;118(3):276-82.e2.\nProgram Prior Authorization/Medical Necessity – Sublingual Immunotherapy (SLIT)\nChange Control\nDate Change\n5/2014 New Program\n5/2015 Administrative changes and updates to references.\n4/2016 Removed SCIT requirement, removed allergen avoidance, updated specialist\nprescriber requirement. References updated.\n7/2016 Added Indiana and West Virginia coverage information.\n11/2016 Administrative change. Added California coverage information.\n4/2017 Odactra added to criteria. State mandate reference language updated.\n3/2018 Annual review. References updated.\n3/2019 Annual review with administrative changes. Modified symptomatic asthma\nto severe, unstable and/or uncontrolled asthma. Added statement regarding\nuse of automated processes and updated references.\n3/2020 Annual review. Updated references.\n3/2021 Annual review. Updated references.\n9/2021 Added clarification around moderate to severe allergic rhinitis based on\nAmerican Academy of Allergy, Asthma & Immunology guidelines.\n3/2022 Updated references.\n© 2025 UnitedHealthcare Services Inc.\n6\n3/2023 Annual review. Updated references.\n3/2024 Annual review. Updated references.\n3/2025 Annual review. No changes.\n© 2025 UnitedHealthcare Services Inc.\n7"
  ]
}